HR
LGND icon

Howe & Rusling’s Ligand Pharmaceuticals LGND Stock Holding History

Howe & Rusling’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-48
Closed -$3K – 986
2020
Q4 		$3K Buy
48
+21
+78% +$1.2K ﹤0.01% 741
2020
Q3 		$2K Hold
27
– – ﹤0.01% 718
2020
Q2 		$2K Buy
+27
New +$1.71K ﹤0.01% 681
2019
Q1 		– Sell
-51
Closed -$4K – 851
2018
Q4 		$4K Hold
51
– – ﹤0.01% 569
2018
Q3 		$9K Buy
+51
New +$7.69K ﹤0.01% 528
2018
Q2 		– Sell
-2,140
Closed -$220K – 888
2018
Q1 		$220K Hold
2,140
– – 0.04% 163
2017
Q4 		$183K Hold
2,140
– – 0.03% 185
2017
Q3 		$182K Hold
2,140
– – 0.03% 182
2017
Q2 		$162K Hold
2,140
– – 0.03% 162
2017
Q1 		$141K Hold
2,140
– – 0.03% 174
2016
Q4 		$136K Sell
2,140
-64
-3% -$4.04K 0.03% 175
2016
Q3 		$140K Hold
2,204
– – 0.03% 167
2016
Q2 		$164K Buy
2,204
+168
+8% +$12.5K 0.04% 144
2016
Q1 		$136K Buy
2,036
+177
+10% +$10.8K 0.03% 173
2015
Q4 		$126K Buy
1,859
+136
+8% +$8.4K 0.03% 184
2015
Q3 		$92K Hold
1,723
– – 0.02% 209
2015
Q2 		$108K Buy
+1,723
New +$94K 0.02% 208

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Howe & Rusling's LGND Position: Q1 2021 in Review

Howe & Rusling sold out of Ligand Pharmaceuticals (LGND) in Q1 2021, closing a stake of 48 shares — an estimated $3K sold.

Howe & Rusling first reported a position in LGND in Q2 2015 and held it in 17 quarters. The position peaked at $220K in Q1 2018. 228 funds tracked by Wall St. Rank hold LGND as of Q1 2021.

  • Howe & Rusling reported no remaining Ligand Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Howe & Rusling sold 48 Ligand Pharmaceuticals shares in Q1 2021, an estimated $3K.
  • Howe & Rusling first reported a position in Ligand Pharmaceuticals in Q2 2015 and held it in 17 quarters.
  • Howe & Rusling's Ligand Pharmaceuticals position peaked at $220K in Q1 2018.
  • 228 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2021.

Based on Howe & Rusling's 13F filing for Q1 2021, filed 13 May 2021.